Background
Methods
Patients
Immunohistocheminal Analysis of EphA3
Interpretation of the immunostaining results
Statistical analysis
Results
EPHA3 immunohistochemistry
Relationship between EPHA3 expression and clinicopathological factors
Variables | EphA3 | |||
---|---|---|---|---|
n
n = 202 | Low
n = 111 (n, %) | High
n = 91 (n, %) |
p value | |
Age | ||||
< 65 | 97 | 60 (61.9) | 37 (38.1) | 0.067 |
≥ 65 | 105 | 51 (48.6) | 54 (51.4) | |
Gender | ||||
Female | 48 | 33 (68.8) | 15 (31.3) | 0.031 |
Male | 154 | 78 (50.6) | 76 (49.4) | |
Main location | ||||
Middle or Lower | 160 | 93 (58.1) | 67 (41.9) | 0.084 |
Upper | 42 | 18 (42.9) | 24 (57.1) | |
WHO pathological type | ||||
Differentiated | 99 | 39 (39.4) | 60 (60.6) | <0.001 |
Undifferentiated | 103 | 72 (69.9) | 31 (30.1) | |
Depth of invasion | ||||
T1 | 87 | 59 (67.8) | 28 (32.2) | 0.002 |
T2/3/4 | 115 | 52 (45.2) | 63 (54.8) | |
Lymph node metastasis | ||||
Negative | 113 | 74 (65.5) | 39 (34.5) | 0.001 |
Positive | 89 | 37 (41.6) | 52 (58.4) | |
Stage | ||||
I | 106 | 72 (67.9) | 34 (32.1) | <0.001 |
II/III | 96 | 39 (40.4) | 57 (59.4) | |
Distant recurrence | ||||
Negative | 152 | 91 (59.9) | 61 (40.1) | 0.021 |
Positive | 50 | 20 (40) | 30 (60) | |
Liver recurrence | ||||
Negative | 194 | 110 (56.7) | 84 (43.3) | 0.024 |
Positive | 8 | 1 (12.5) | 7 (87.5) | |
Peritoneal recurrence | ||||
Negative | 182 | 99 (54.4) | 83 (45.6) | 0.814 |
Positive | 20 | 12 (60) | 8 (40) | |
HER2 | ||||
Negative | 186 | 107 (57.5) | 79 (42.5) | 0.017 |
Positive | 16 | 4 (25) | 12 (75) |
Correlation between EPHA3 expression and survival
Variables | Univariate (log-rank) | Multivariate | |||
---|---|---|---|---|---|
5-years RFS (%) |
p
| HR | 95% CI |
p
| |
Age | |||||
< 65 | 75.5 | 0.809 | |||
≥ 65 | 74.5 | ||||
Gender | |||||
Female | 77.1 | 0.655 | |||
Male | 74.4 | ||||
Main location | |||||
Middle or Lower | 80.1 | 0.001 | 1 | ||
Upper | 55.8 | 1.684 | 0.937–3.029 | 0.082 | |
WHO pathological type | |||||
Differentiated | 84 | 0.03 | 1 | ||
Undifferentiated | 66.3 | 1.616 | 0.841–3.103 | 0.149 | |
Depth of invasion | |||||
T1 | 97.7 | <0.001 | 1 | ||
T2,3,4 | 58.1 | 9.333 | 2.183–39.911 | 0.003 | |
Lymph node metastasis | |||||
Negative | 94.7 | <0.001 | 1 | ||
Positive | 50.5 | 5.734 | 2.349–13.997 | <0.001 | |
EPHA3 | |||||
Low | 82.0 | 0.014 | 1 | ||
High | 67.0 | 1.313 | 0.705–2.447 | 0.391 | |
HER2 | |||||
Negative | 75.5 | 0.538 | |||
Positive | 68.8 |
Variables | Univariate (log-rank) | Multivariate | |||
---|---|---|---|---|---|
5-years OS (%) |
p
| HR | 95% CI |
p
| |
Age | |||||
< 65 | 76.5 | 0.578 | |||
≥ 65 | 74.5 | ||||
Gender | |||||
Female | 79.2 | 0.516 | |||
Male | 74.4 | ||||
Main location | |||||
Middle or Lower | 80.1 | 0.001 | 1 | ||
Upper | 58.1 | 1.654 | 0.907–3.017 | 0.101 | |
WHO pathological type | |||||
Differentiated | 83 | 0.01 | 1 | ||
Undifferentiated | 68.3 | 1.475 | 0.766–2.842 | 0.246 | |
Depth of invasion | |||||
T1 | 97.7 | <0.001 | 1 | ||
T2,3,4 | 59 | 8.785 | 2.038–37.881 | 0.004 | |
Lymph node metastasis | |||||
Negative | 94.7 | <0.001 | 1 | ||
Positive | 51.6 | 5.928 | 2.417–14.537 | <0.001 | |
EPHA3 | |||||
Low | 82.0 | 0.026 | 1 | ||
High | 68.1 | 1.147 | 0.603–2.181 | 0.677 | |
HER2 | |||||
Negative | 75.76.15 | 0.431 | |||
Positive | 68.8 |